๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chengdu
Clinical trial register · China

Clinical Trials in Chengdu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
West China Hospital162 AstraZeneca148 Janssen Research & Development, LLC55 Hoffmann-La Roche44 Sichuan University44
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Chengdu

1291 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Phase โ…ก Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
NCT06962865Non-Small Cell Lung Cancer
RemeGen Co., Ltd.
Phase 2
80
Beijing, Binzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou
2025-06-30
Active, closed
Spirulina-Derived Product Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors
NCT07040969Radiation-induced Oral Mucositis
West China Hospital
Phase 2
70
Chengdu
2025-06-27
Recruiting
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT07082738Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 2
987
Baotou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-06-27
Active, closed
Hyperkalemia Quality Improvement Program (HK-QIP) Study
NCT06884267Hyperkalemia
AstraZeneca
Not applicable
1,000
Beijing, Benxi, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuyang
2025-06-25
Recruiting
A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)
NCT07035626Radiation-induced Xerostomia
West China Hospital
Phase 1/2
58
Chengdu
2025-06-25
Active, closed
A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
NCT06843408Chronic Graft-versus-host-disease
Incyte Corporation
Phase 1/2
32
Beijing, Chengdu, Chongoing, Guangzhou, Hangzhou, Shanghai, Tianjin, Wuhan
2025-06-25
Recruiting
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
NCT06951464Non-Small Cell Lung Cancer
Sichuan University
Phase 2
40
Chengdu
2025-06-25
Recruiting
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
NCT06959095Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
Phase 3
981
Changsha, Chengdu, Guangzhou, Hangzhou, Jiangmen, Jiangxi, Mianyang, Qingyuan
2025-06-20
Recruiting
A Study in Children With Achondroplasia
NCT07301463Achondroplasia
Abbisko Therapeutics Co, Ltd
Observational
260
Beijing, Guangzhou, Zhengzhou, Wuhan, Shanghai, Chengdu, Hangzhou
2025-06-20
Recruiting
Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage
NCT07026994Cerebral Amyloid Angiopathy, Intracerebral Hemorrhage Lobar
Huashan Hospital
Phase 2
80
Beijing, Chengdu, Shanghai
2025-06-18
Recruiting
Association Between Early Recurrence and Long-Term Recurrence After Pulsed Field Ablation for Atrial Fibrillation: Prospective Real-World Evidence From China
NCT07518966Atrial Fibrillation (AF)
West China Hospital
Observational
1,200
Chengdu
2025-06-16
Not yet open
Effects of Ropivacaine Concentrations on Prolonged Labor Analgesia
NCT07007650Labor Analgesia, Prolonged, Ropivacaine, Concentration
Chengdu Jinjiang Maternity and Child Health Hospital
Not applicable
100
Chengdu
2025-06-14
Recruiting
HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors
NCT06822998Advanced Solid Tumors
HighField Biopharmaceuticals Corporation
Phase EARLY_PHASE1
10
Chengdu
2025-06-11
Recruiting
FIH Study of PFLotus in Persistent Atrial Fibrillation
NCT07301190Persistent Atrial Fibrillation
The Third People's Hospital of Chengdu
Not applicable
40
Chengdu
2025-06-11
Active, closed
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma
NCT07010120HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy
West China Hospital
Phase 1/2
29
Chengdu
2025-06-10
Recruiting
The AIRTIVITYโ„ข Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892Bronchiectasis
Boehringer Ingelheim
Phase 3
1,755
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2025-06-09
Recruiting
The Effect of Oral Oxytocin and Atosiban on Social Attention
NCT07093060Healhty
University of Electronic Science and Technology of China
Phase EARLY_PHASE1
250
Chengdu
2025-06-09
Active, closed
A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
NCT06786338IgA Nephropathy (IgAN), C3 Glomerulopathy, IC-MPGN
Suzhou Sanegene Bio Inc.
Phase 2
45
Beijing, Changsha, Chengdu, Guiyang, Hangzhou, Shanghai, Yangzhou, Yinchuan
2025-06-06
Recruiting
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
NCT06962839Macular Edema
Boehringer Ingelheim
Phase 2
300
Chengdu, Shanghai, Shenyang, Shijiazhuang, Taiyuan
2025-06-05
Recruiting
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies
NCT07004244Malignant Tumors
Sichuan University
Phase 1
20
Chengdu
2025-06-05
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
Janssen Research & Development, LLC
Phase 3
600
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan
2025-06-04
Recruiting
Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease
NCT07267117Heart Valve Disease, Mitral Valve (MV) Regurgitation, Mitral Valve Disease, Mitral Valve Stenosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Fuzhou, Wuhan, Changsha, Shenyang, Xi'an, Qingdao, Chengdu, รœrรผmqi
2025-06-01
Recruiting
Adaptive Intervention Model for Hypertension Self-Management in Rural Areas: A Doctor-Patient Interaction Approach
NCT06869031Hypertension Self-management, Hypertension
Yuju Wu
Not applicable
320
Chengdu
2025-06-01
Not yet open
Safety and Efficacy of Connecting the Residual Ear to the Cartilage Scaffold in First- vs. Second-Stage Surgery
NCT06763991Microtia, Outcome Assessment, RCT, Surgery Related Complications Rate
Sichuan Provincial People's Hospital
Not applicable
78
Chengdu
2025-06-01
Not yet open
Transvaginal Diverticulum Wall Filling and Coverage Technique for Treating Female Circumferential Urethral Diverticulum
NCT07006753Circumferential Female Urethral Diverticulum
West China Hospital
Phase 2
30
Chengdu
2025-06-01
Recruiting
Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children
NCT07022834Langerhans Cell Histiocytosis (LCH)
West China Second University Hospital
Phase 2
20
Chengdu
2025-06-01
Recruiting
Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Esophageal Carcinoma
NCT06979869Esophageal Cancer
Xijing Hospital
Observational
300
Wuwei, Shantou, Zhaoqing, Zhengzhou, Xi'an, Yanโ€™an, Taiyuan, Chengdu
2025-05-26
Recruiting
Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE
NCT06853535Acute Ischemic Stroke, Clopidogrel Resistance
Sichuan Provincial People's Hospital
Phase 3
5,138
Chengdu
2025-05-23
Recruiting
A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors
NCT07050459Locally Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
220
Beijing, Haerbin, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Chengdu
2025-05-20
Recruiting
Exergame-assisted Simultaneous Motor-cognitive Training for Middle-aged Old Adults in China
NCT07085663Subjective Cognitive Decline
The Hong Kong Polytechnic University
Not applicable
30
Chengdu
2025-05-20
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370Heart Failure
Boehringer Ingelheim
Phase 3
4,200
Beijing, Changchun, Changde, Changsha, Chengdu, Chenzhou, Chongqing, Dalian
2025-05-20
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472Obesity, Overweight, Type 2 Diabetes
Eli Lilly and Company
Phase 3
600
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-19
Active, closed
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
NCT06898957Small Cell Lung Cancer
Amgen
Phase 1
29
Jinan, Chengdu, Fuzhou
2025-05-16
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792Obesity, Overweight, Type 2 Diabetes
Eli Lilly and Company
Phase 3
1,400
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-15
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459Obesity, Overweight
Eli Lilly and Company
Phase 3
800
Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi
2025-05-15
Active, closed
A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery
NCT06890533Pain
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Phase 3
560
Cangzhou, Changde, Changsha, Chengdu, Chongqing, Chโ€™ang-chโ€™un, Dalian, Deyang
2025-05-14
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891Moderately to Severely Active Crohns Disease
Hoffmann-La Roche
Phase 3
425
Ganzhou, Kunming, Jinhua, Beijing, Chengdu, Guangzhou, Haikou, Huizhou
2025-05-12
Recruiting
Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors
NCT06927297Advanced Solid Tumor Malignancies, Advanced Solid Malignancies
West China Hospital
Phase 1
12
Chengdu
2025-05-09
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785Hepatocellular Carcinoma
AstraZeneca
Phase 3
1,220
Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Deyang, Fuzhou
2025-05-06
Not yet open
NAD+ Supplement๏ผˆNMN๏ผ‰With Radioimmunotherapy in Advanced NSCLC
NCT06966583Solid Tumor, Non Small Cell Lung Cancer
Sichuan University
Phase 1
20
Chengdu
2025-05-01
Not yet open
Regret Emotion After Thyroidectomy in Low-Risk Papillary Thyroid Cancer
NCT06804863Thyroid Cancer, Regret
West China Hospital
Not applicable
600
Chengdu
2025-05-01
Not yet open
A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B
NCT06926647HBV, Chronic Hepatitis b
Beijing 302 Hospital
Observational
2,000
Ankang, Anyang, Beihai, Beijing, Binzhou, Changzhi, Changzhou, Chengdu
2025-05-01
Not yet open
Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase
NCT06961201Extensive-stage Small Cell Lung Cancer (ES-SCLC), The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
94
Chengdu
2025-05-01
Not yet open
A Bioequivalence Study of Two Different Processes of PEG-rhGH Preparations
NCT06840691Pediatric Growth Hormone Deficiency (PGHD)
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
87
Chengdu
2025-05
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
Eli Lilly and Company
Phase 3
487
Beijing, Changchun, Changde, Chengdu, Chongqing, Jinan, Lishui, Luoyang Shi
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
Eli Lilly and Company
Phase 3
487
Beijing, Changchun, Changde, Chengdu, Chongqing, Jinan, Lishui, Luoyang Shi
2025-04-30
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
Eli Lilly and Company
Phase 3
974
Beijing, Changchun, Changde, Chengdu, Chongqing, Jinan, Lishui, Luoyang Shi
2025-04-30
Active, closed
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 1/2
31
Beijing, Chengdu, Shanghai, Wuhan
2025-04-29
Recruiting
Sapien 3 Transcatheter Aortic Valve Replacement in Young Aortic Valve Stenosis Patients From China
NCT06830499AORTIC VALVE DISEASES, Bicuspid Aortic Valve (BAV)
Xijing Hospital
Observational
450
Xi'an, Chengdu, Beijing, Shanghai
2025-04-24
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
BioNTech SE
Phase 1/2
380
Bengbu, Changchun, Chengdu, Chongqing, Huizhou, Nanning, Shanghai, Xi'an
2025-04-23
By invitation
Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).
NCT06737354nAMD
InnoVec Biotherapeutics Inc.
Phase 1
18
Chengdu
2025-04-22
Recruiting
a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors
NCT06878612Polyphenols, Cancer Vaccine, Advanced Solid Tumor
Xingchen Peng
Phase 1
9
Chengdu
2025-04-21
Recruiting
A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer
NCT07101679Locally Advanced Pancreatic Ductal Adenocarcinoma
West China Hospital
Phase 2
23
Chengdu
2025-04-16
Active, closed
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
NCT06900543Unresectable Hepatocellular Carcinoma
Chengdu New Radiomedicine Technology Co. LTD.
Phase 3
108
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Shenyang, Xiโ€™an, Chengdu
2025-04-15
Active, closed
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
NCT06866574Penile/Perineal /Perianal Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Penile/Perianal/Perineal Cancer, Anal Cancer
Xiamen University
Phase 3
9,300
Fuzhou, Chengdu, Kunming, Hangzhou
2025-04-11
Active, closed
Photobiomodulation Therapy vs. Alpha-Lipoic Acid in Burning Mouth Syndrome Treatment
NCT07381361Burning Mouth Syndrome, Low Level Laser Therapy
Lu Jiang
Not applicable
60
Chengdu
2025-04-10
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277Carcinoma, Non-Small Cell Lung
AstraZeneca
Phase 3
830
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2025-04-10
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
Hoffmann-La Roche
Phase 3
450
Xiangyang, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jiangmen
2025-04-09
Recruiting
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
NCT05066217Lennox Gastaut Syndrome
Epygenix
Phase 3
260
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Jinan
2025-04-09
Recruiting
Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes
NCT06861062Diabetes Mellitus, Type 2
Huazhong University of Science and Technology
Not applicable
2,500
Nanning, Tangshan, Shiyan, Wuhan, Chengdu
2025-04-08
Recruiting
Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma
NCT06950827Hepatocellular Carcinoma, Hepatectomy, Laparoscopic Hepatectomy
West China Hospital
Observational
400
Chengdu
2025-04-05
Recruiting
Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma
NCT06950814Sarcomatoid Carcinoma, Liver Cancer, Adjuvant Therapy
West China Hospital
Observational
50
Chengdu
2025-04-05
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Gilead Sciences
Phase 3
695
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-04-04
Recruiting
Phase I Clinical Study of ฮฑ-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
NCT06348797Small Cell Lung Cancer Extensive Stage
Sichuan University
Phase 1
30
Chengdu
2025-04-03
Not yet open
A Single-center Study of CM313 in Patients With Pemphigus
NCT06904040Pemphigus
Sichuan Provincial People's Hospital
Not applicable
20
Chengdu
2025-04-01
By invitation
Protective Effect of Ulinastatin and Thymosin ฮฑ1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)
NCT06966687Aortic Dissection, Aortic Dissection Aneurysm
Nanjing Medical University
Not applicable
200
Beijing, Guangzhou, Shanghai, Chengdu
2025-04-01
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
Sanofi
Phase 3
300
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Wuhan
2025-04-01
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945Alopecia Areata
Pfizer
Phase 3
674
Beijing, Chongqing, Guangzhou, Changsha, Nanchang, Shanghai, Chengdu, Kunming
2025-04-01
Recruiting
Pain Relief From Dysmenorrhea Employing taVNS
NCT06912386Dysmenorrhea Primary
University of Electronic Science and Technology of China
Not applicable
20
Chengdu
2025-04-01
Not yet open
Clinical Study on the Efficacy and Safety of SHR-4597 Inhalant in Adult Patients With Asthma
NCT06940700Asthma
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
60
Chengdu
2025-04
Not yet open
Study on the Ablation of Persistent Atrial Fibrillation Using Pulsed Electric Fields Under Different Surgical Procedures
NCT06671197Persistent Atrial Fibrillation
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
436
Chengdu
2025-03-31
Active, closed
The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)
NCT06921486Obesity and Overweight
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase 2/3
1,003
Beijing, Changzhou, Chengdu, Guangzhou, Guangzhusi, Guizhou, Hangzhou, Harbin
2025-03-31
Recruiting
Clinical Characteristics and Epidemiology of Chronic Critically Ill Patients in China
NCT07372742Chronic Critically Ill
West China Hospital
Observational
459
Chengdu
2025-03-29
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
AstraZeneca
Phase 3
600
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2025-03-27
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 3
700
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Foshan, Guangzhou
2025-03-27
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781Esophageal Squamous Cell Carcinoma
Daiichi Sankyo
Phase 3
510
Anyang, Beijing, Changchun, Changzhou, Chengdu, Fuzhou, Harbin, Hefei
2025-03-27
Recruiting
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
NCT06795022Hepatocellular Carcinoma
AstraZeneca
Phase 1/2
304
Chengdu, Guangzhou, Harbin, Shanghai
2025-03-27
Recruiting
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT06932263Asthma
AstraZeneca
Phase 2
540
Baotou, Changchun, Chengdu, Chongqing, Guangzhou, Haikou, Hefei, Hohhot
2025-03-26
Recruiting
Allogeneic UCB-derived CAR-T for SLE
NCT07274059SLE - Systemic Lupus Erythematosus
Chengdu Ucello Biotechnology Co., Ltd.
Phase EARLY_PHASE1
48
Yancheng, Chengdu
2025-03-26
Recruiting
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
NCT06818643Advanced Solid Tumors, Malignant Neoplasm
Merck Sharp & Dohme LLC
Phase 1/2
270
Beijing, Chongqing, Changsha, Changchun, Chengdu
2025-03-25
Recruiting
BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy
NCT07715136Inflammatory Myopathy
iCell Gene Therapeutics
Phase 1
10
Chengdu
2025-03-20
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
Daiichi Sankyo
Phase 3
582
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2025-03-19
Recruiting
Prone Positioning in ARDS: Predicting Neurological Complications Via Cerebral Hemodynamics
NCT06967285ARDS (Moderate or Severe)
Sichuan Provincial People's Hospital
Observational
50
Chengdu
2025-03-19
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 3
990
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-03-18
Active, closed
cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia
NCT06686485Concomitant Procedures, Atrial Fibrillation, PFA, LAAC
Boston Scientific Corporation
Observational
433
Suzhou, Beijing, Chengdu, Guangzhou, Guiyang, Hangzhou, Jinan, Kunming
2025-03-18
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878Moderately to Severely Active Crohns Disease
Hoffmann-La Roche
Phase 3
600
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2025-03-17
Recruiting
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
NCT06831175Adrenal Cortical Carcinoma, Adrenal Cortical Cancer, Adrenal Cancer
West China Hospital
Phase 2
28
Chengdu
2025-03-15
Active, closed
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048Neovascular Age-related Macular Degeneration (nAMD)
Hoffmann-La Roche
Phase 4
274
Beijing, Chengdu, Guangzhou, Shanghai, Wuhan
2025-03-14
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
AstraZeneca
Phase 3
11,300
Baotou, Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chifeng
2025-03-14
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
AstraZeneca
Phase 2
80
Beijing, Chengdu, Harbin, Shanghai, Wuhan, Zhengzhou
2025-03-12
Active, closed
Single-ascending Dose Study of Kylo-12 in Healthy Subjects
NCT06783881Hypertriglyceridemia
Kylonova (Xiamen) Biopharma co., LTD.
Phase 1
50
Chengdu
2025-03-12
Recruiting
A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06716138Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Avistone Biotechnology Co., Ltd.
Phase 1
96
Fuzhou, Guangzhou, Shanghai, Chengdu
2025-03-06
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
5,000
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongwan
2025-03-03
Recruiting
A Phase โ…ข Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 3
840
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou
2025-03-01
Recruiting
taVNS Effects on Fear Ratings in Naturalistic Context
NCT06975124Healthy Participants
University of Electronic Science and Technology of China
Phase 1
70
Chengdu
2025-03-01
Recruiting
Visual Adaptation and Quality of Life After Different IOL Implantation Strategies
NCT07740590Cataract, Aphakia - Lens Capsule Present
Sichuan Academy of Medical Sciences
Observational
264
Chengdu
2025-03-01
Not yet open
Trial of Gum Chewing to Enhance the Restoration of Intestinal Motility in Colorectal Cancer Surgery
NCT06860685Colorectal Cancer (CRC)
Sichuan Cancer Hospital and Research Institute
Phase 1/2
292
Chengdu
2025-03-01
Recruiting
Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)
NCT06859684Intrahepatic Cholangiocarcinoma (Icc), HAIC, Durvalumab
West China Hospital
Phase 2
25
Chengdu
2025-03-01
Not yet open
A Clinical Trial to Evaluate the Efficacy and Safety of Methoxyethyl Etomidate Hydrochloride for Sedation/Anesthesia During Gastroscopy/Colonoscopy
NCT06858852Gastroscopy, Colonoscopy
Ahon Pharmaceutical Co., Ltd.
Phase 3
270
Beijing, Shenzhen, Chengdu, Guangyuan, Yibin
2025-03
Recruiting
Percutaneous Repair for Drug - Resistant Epilepsy by Intervention of Closing the Patent Foramen Ovale๏ผˆPREDICT-PFO Trial๏ผ‰
NCT06863350Epilepsy (treatment Refractory)
Sichuan University
Not applicable
180
Chengdu
2025-02-28
Rows per page Showing 501–600 of 1291
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/chengdu?page=6

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,291 of those studies with a site in Chengdu.

How many clinical trials are recruiting in Chengdu?

732 of the 1,291 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 177 have not yet opened recruitment, 354 are active but closed to new participants, and 28 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.